Journal of Zhejiang University SCIENCE B

, Volume 11, Issue 1, pp 22–26 | Cite as

Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern

  • Bo Zhang
  • Qiu-ping Xie
  • Shun-liang Gao
  • Yan-biao Fu
  • Yu-lian Wu
Case Report


Somatostatinoma is a very rare neuroendocrine tumor that originates from D cells and accounts for less than 1% of all gastrointestinal endocrine tumors. The duodenum is the most frequent site for this tumor, followed by the pancreas. We here describe a 46-year-old Chinese woman who developed pancreatic somatostatinoma presenting with the characteristic “inhibitory” syndrome, but the symptoms were obscure and seemingly uncorrelated. This case is also unique for its large tumor size and mixed pathological pattern. Distal pancreatectomy was performed, and the patient has remained well since operation. As the syndromes of somatostatinoma may be obscure and atypical, clinicians should review all clinical findings to obtain an accurate diagnosis. Aggressive surgery is preferred to improve the survival.

Key words

Neuroendocrine tumor Somatostatinoma Somatostatinoma syndrome Pancreatic hormone-producing tumor Pancreatectomy 

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anene, C., Thompson, J.S., Saigh, J., Badakhsh, S., Ecklund, R.E., 1995. Somatostatinoma: atypical presentation of a rare pancreatic tumor. Am. J. Gastroenterol., 90(5): 819–821.PubMedGoogle Scholar
  2. Barahona-Garrido, J., Aguirre-Gutierrez, R., Gutierrez-Manjarrez, J.I., Tellez-Avila, F.I., Lopez-Arce, G., Fomperoza-Torres, A., Criales, S., Sanchez-Cortes, E., Sarti, H.M., Yamamoto-Furusho, J.K., 2009. Association of GIST and somatostatinoma in a patient with type-1 neurofibromatosis: is there a common pathway? Am. J. Gastroenterol., 104(3):797–799. [doi:10.1038/ajg.2008.133]CrossRefPubMedGoogle Scholar
  3. Cao, X.P., Liu, Y.Y., Xiao, H.P., Li, Y.B., Wang, L.T., Xiao, P., 2009. Pancreatic somatostatinoma characterized by extreme hypoglycemia. Chin. Med. J. (Engl.), 122(14): 1709–1712.Google Scholar
  4. House, M.G., Yeo, C.J., Schulick, R.D., 2002. Periampullary pancreatic somatostatinoma. Ann. Surg. Oncol., 9(9):869–874. [doi:10.1007/BF02557523]CrossRefPubMedGoogle Scholar
  5. Janson, E.T., 2005. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J. Endocrinol. Invest., 28(11 Suppl. International): 137–140.PubMedGoogle Scholar
  6. Klöppel, G., Perren, A., Heitz, P.U., 2004. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. N. Y. Acad. Sci., 1014(1):13–27. [doi:10.1196/annals.1294.002]CrossRefPubMedGoogle Scholar
  7. Konomi, K., Chijiiwa, K., Katsuta, T., Yamaguchi, K., 1990. Pancreatic somatostatinoma: a case report and review of the literature. J. Surg. Oncol., 43(4):259–265. [doi:10.1002/jso.2930430414]CrossRefPubMedGoogle Scholar
  8. Larsson, L.I., Hirsch, M.A., Holst, J.J., Ingemansson, S., Kuhl, C., Jensen, S.L., Lundqvist, G., Rehfeld, J.F., Schwartz, T.W., 1977. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet, 309(8013): 666–668. [doi:10.1016/S0140-6736(77)92113-4]CrossRefGoogle Scholar
  9. Levy-Bohbot, N., Merle, C., Goudet, P., Delemer, B., Calender, A., Jolly, D., Thiefin, G., Cadiot, G., 2004. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol., 28(11):1075–1081.PubMedGoogle Scholar
  10. Maki, M., Kaneko, Y., Ohta, Y., Nakamura, T., Machinami, R., Kurokawa, K., 1995. Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern. Med., 34(7):661–665. [doi:10.2169/internalmedicine.34.661]CrossRefPubMedGoogle Scholar
  11. Marakis, G., Ballas, K., Rafailidis, S., Alatsakis, M., Patsiaoura, K., Sakadamis, A., 2005. Somatostatinproducing pancreatic endocrine carcinoma presented as relapsing cholangitis: a case report. Pancreatology, 5(2–3):295–299. [doi:10.1159/000085286]CrossRefPubMedGoogle Scholar
  12. Moayedoddin, B., Booya, F., Wermers, R.A., Lloyd, R.V., Rubin, J., Thompson, G.B., Fatourechi, V., 2006. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr. Pract., 12(4):394–400.PubMedGoogle Scholar
  13. Mozell, E., Stenzel, P., Woltering, E.A., Rosch, J., O’Dorisio, T.M., 1990. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr. Probl. Surg., 27(6):309–386. [doi:10.1016/0011-3840(90)90025-Z]CrossRefGoogle Scholar
  14. Nesi, G., Marcucci, T., Rubio, C.A., Brandi, M.L., Tonelli, F., 2008. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J. Gastroenterol. Hepatol., 23(4):521–526. [doi:10.1111/j.1440-1746.2007.05053.x]CrossRefPubMedGoogle Scholar
  15. Sakazaki, S., Umeyama, K., Nakagawa, H., Hashimoto, H., Kamino, K., Mitsuhashi, T., Yamaguchi, K., 1983. Pancreatic somatostatinoma. Am. J. Surg., 146(5):674–679. [doi:10.1016/0002-9610(83)90310-0]CrossRefPubMedGoogle Scholar
  16. Sato, T., Konishi, K., Kimura, H., Maeda, K., Yabushita, K., Tsuji, M., Demachi, H., Miwa, A., 2000. Strategy for pancreatic endocrine tumors. Hepatogastroenterology, 47(32):537–539.PubMedGoogle Scholar
  17. Soga, J., Yakuwa, Y., 1999. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J. Exp. Clin. Cancer Res., 18(1):13–22.PubMedGoogle Scholar
  18. Stelow, E.B., Woon, C., Pambuccian, S.E., Thrall, M., Stanley, M.W., Lai, R., Mallery, S., Gulbahce, H.E., 2005. Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. Diagn. Cytopathol., 33(2):100–105. [doi:10.1002/dc.20305]CrossRefPubMedGoogle Scholar
  19. Suzuki, H., Kuwano, H., Masuda, N., Hashimoto, S., Kanoh, K., Nomoto, K., Shimura, T., Katoh, H., 2008. Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepatogastroenterology, 55(85):1242–1245.PubMedGoogle Scholar
  20. Tjon, A.T.R.T., Jansen, J.B., Falke, T.H., Lamers, C.B., 1994. Imaging features of somatostatinoma: MR, CT, US, and angiography. J. Comput. Assist. Tomogr., 18(3):427–431.CrossRefGoogle Scholar
  21. Tomono, H., Kitamura, H., Iwase, M., Kuze, S., Toyoda, F., Mori, N., Tamoto, E., Inuzuka, K., Fujita, H., Konishi, Y., Naito, M., Tanioka, F., 2003. A small, incidentally detected pancreatic somatostatinoma: report of a case. Surg. Today, 33(1):62–65. [doi:10.1007/s005950300012]CrossRefPubMedGoogle Scholar
  22. Vinik, A.I., Strodel, W.E., Eckhauser, F.E., Moattari, A.R., Lloyd, R., 1987. Somatostatinomas, ppomas, neurotensinomas. Semin. Oncol., 14(3):263–281.PubMedGoogle Scholar
  23. Zhang, Z.Y., Zhang, R., Wang, L., Shen, C., Yan, J.Q., Chen, Y.J., Li, Q.Y., Yang, W.P., Peng, C.H., Li, H.W., Zhou, G.W., 2008. Diagnosis and treatment of pancreatic somatostatinoma: a case report. Chin. Med. J. (Engl.), 121(22):2363–2365.Google Scholar

Copyright information

© Zhejiang University and Springer Berlin Heidelberg 2010

Authors and Affiliations

  • Bo Zhang
    • 1
  • Qiu-ping Xie
    • 1
  • Shun-liang Gao
    • 1
  • Yan-biao Fu
    • 2
  • Yu-lian Wu
    • 1
  1. 1.Department of Surgery, the Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Department of Pathology, the Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations